Literature DB >> 28899017

Cortical functional hyperconnectivity in a mouse model of depression and selective network effects of ketamine.

Alexander McGirr1,2, Jeffrey LeDue1,2, Allen W Chan1,2, Yicheng Xie1,2, Timothy H Murphy1,2.   

Abstract

See Huang and Liston (doi:10.1093/awx166) for a scientific commentary on this article.Human depression is associated with glutamatergic dysfunction and alterations in resting state network activity. However, the indirect nature of human in vivo glutamate and activity assessments obscures mechanistic details. Using the chronic social defeat mouse model of depression, we determine how mesoscale glutamatergic networks are altered after chronic stress, and in response to the rapid acting antidepressant, ketamine. Transgenic mice (Ai85) expressing iGluSnFR (a recombinant protein sensor) permitted real-time in vivo selective characterization of extracellular glutamate and longitudinal imaging of mesoscale cortical glutamatergic functional circuits. Mice underwent chronic social defeat or a control condition, while spontaneous cortical activity was longitudinally sampled. After chronic social defeat, we observed network-wide glutamate functional hyperconnectivity in defeated animals, which was confirmed with voltage sensitive dye imaging in an independent cohort. Subanaesthetic ketamine has unique effects in defeated animals. Acutely, subanaesthetic ketamine induces large global cortical glutamate transients in defeated animals, and an elevated subanaesthetic dose resulted in sustained global increase in cortical glutamate. Local cortical inhibition of glutamate transporters in naïve mice given ketamine produced a similar extracellular glutamate phenotype, with both glutamate transients and a dose-dependent accumulation of glutamate. Twenty-four hours after ketamine, normalization of depressive-like behaviour in defeated animals was accompanied by reduced glutamate functional connectivity strength. Altered glutamate functional connectivity in this animal model confirms the central role of glutamate dynamics as well as network-wide changes after chronic stress and in response to ketamine.
© The Author (2017). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  affective disorders; associational areas; drug treatment; imaging

Mesh:

Substances:

Year:  2017        PMID: 28899017     DOI: 10.1093/brain/awx142

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  18 in total

1.  In vivo microstimulation with cathodic and anodic asymmetric waveforms modulates spatiotemporal calcium dynamics in cortical neuropil and pyramidal neurons of male mice.

Authors:  Kevin C Stieger; James R Eles; Kip A Ludwig; Takashi D Y Kozai
Journal:  J Neurosci Res       Date:  2020-06-26       Impact factor: 4.164

Review 2.  Toward Circuit Mechanisms of Pathophysiology in Depression.

Authors:  Timothy Spellman; Conor Liston
Journal:  Am J Psychiatry       Date:  2020-05-01       Impact factor: 18.112

3.  Intracortical microstimulation pulse waveform and frequency recruits distinct spatiotemporal patterns of cortical neuron and neuropil activation.

Authors:  Kevin C Stieger; James R Eles; Kip A Ludwig; Takashi D Y Kozai
Journal:  J Neural Eng       Date:  2022-03-31       Impact factor: 5.043

Review 4.  Letting the little light of mind shine: Advances and future directions in neurochemical detection.

Authors:  Nikki Tjahjono; Yihan Jin; Alice Hsu; Michael Roukes; Lin Tian
Journal:  Neurosci Res       Date:  2021-11-30       Impact factor: 2.904

5.  The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.

Authors:  Jennifer Swainson; Alexander McGirr; Pierre Blier; Elisa Brietzke; Stéphane Richard-Devantoy; Nisha Ravindran; Jean Blier; Serge Beaulieu; Benicio N Frey; Sidney H Kennedy; Roger S McIntyre; Roumen V Milev; Sagar V Parikh; Ayal Schaffer; Valerie H Taylor; Valérie Tourjman; Michael van Ameringen; Lakshmi N Yatham; Arun V Ravindran; Raymond W Lam
Journal:  Can J Psychiatry       Date:  2020-11-11       Impact factor: 4.356

6.  Interactions between stimuli-evoked cortical activity and spontaneous low frequency oscillations measured with neuronal calcium.

Authors:  Wei Chen; Kicheon Park; Yingtian Pan; Alan P Koretsky; Congwu Du
Journal:  Neuroimage       Date:  2020-01-20       Impact factor: 6.556

7.  In vivo imaging of calcium and glutamate responses to intracortical microstimulation reveals distinct temporal responses of the neuropil and somatic compartments in layer II/III neurons.

Authors:  James R Eles; Takashi D Y Kozai
Journal:  Biomaterials       Date:  2020-01-07       Impact factor: 12.479

8.  Activation of the phagocyte NADPH oxidase/NOX2 and myeloperoxidase in the mouse brain during pilocarpine-induced temporal lobe epilepsy and inhibition by ketamine.

Authors:  Fatma Tannich; Asma Tlili; Coralie Pintard; Amina Chniguir; Bruno Eto; Pham My-Chan Dang; Ouajdi Souilem; Jamel El-Benna
Journal:  Inflammopharmacology       Date:  2019-10-30       Impact factor: 4.473

9.  Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation.

Authors:  R N Moda-Sava; M H Murdock; P K Parekh; R N Fetcho; B S Huang; T N Huynh; J Witztum; D C Shaver; D L Rosenthal; E J Alway; K Lopez; Y Meng; L Nellissen; L Grosenick; T A Milner; K Deisseroth; H Bito; H Kasai; C Liston
Journal:  Science       Date:  2019-04-12       Impact factor: 63.714

10.  Ketamine ameliorates oxidative stress-induced apoptosis in experimental traumatic brain injury via the Nrf2 pathway.

Authors:  Jinwei Liang; Shanhu Wu; Wenxi Xie; Hefan He
Journal:  Drug Des Devel Ther       Date:  2018-04-16       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.